Back
Article
Oppenheimer Maintains Outperform on Aardvark Therapeutics, Lowers Price Target to $21
Benzinga Newsdesk  |  Mar 02, 2026 14:59  |  Source: www.benzinga.com
Oppenheimer analyst Leland Gershell maintains Aardvark Therapeutics (NASDAQ:AARD) with a Outperform and lowers the price target from $35 to $21.
Comments
  • No comments yet. Be the first to comment!

Login to comment